We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://xitter.cf/t.co/woIbYTUlEv
Philadelphia and RTP
Joined March 2009
- Tweets11.1K
- Following969
- Followers94.5K
- Likes2.4K
#News for #Investors and #Media: Today @US_FDA has approved our first-in-class treatment for chronic hepatitis B (CHB).
This approval reflects our commitment to innovation in liver disease, where significant unmet need remains.
Learn more: gsk.to/4z5NgfC
#News for #Investors and #Media:
The US Food and Drug Administration (FDA) has approved a new indication for one of our immunotherapies. Read more: gsk.to/4zCl4Rf
Building on our $30 billion commitment to US innovation, R&D and manufacturing, today we are celebrating the development of our Upper Merion Flex Factory. By expanding our presence in Pennsylvania, this factory will deliver best-in-class new medicines for respiratory disease and cancer.
@GovernorShapiro @PAChamber @TradeGov @montco_pa @ChamberPHL @SelectUSA
#News for #Investors and #Media:
Today, we announced the US FDA accepted the application for one of our immuno-oncology therapies for priority review. Learn more: gsk.to/4gO7q71
On World Hepatitis Day, we’re raising awareness of viral hepatitis and recognizing the importance of early and more complete testing in hepatitis B.
Learn more about complete testing at: hepatitisbtesting.com
#WorldHepatitisDay #HepB #HepatitisB #LiverHealth #TestingMatters
GSK US retweeted
Today, we’re announcing a £400 million investment in UK life sciences, including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration and accelerate GSK R&D.
GSK US retweeted
News for #Investors and #Media
Watch our CEO Luke Miels as he shares our strong Q2 core performance, continued momentum and plans to accelerate our R&D, including a new flagship R&D centre in Cambridge.
Find out more: gsk.to/4pG56BQ
#Q2Results $GSK
GSK US retweeted
#News for #Investors and #Media: We’ll be at #AIDS2026 with @ViiVHC, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline.
Find out more in the press release: gsk.to/4fdROcs
Our mission: to leave no person living with HIV behind.
#News for #Media and #Investors: Today @US_FDA has approved our oral anti-infective for complicated urinary tract infections (cUTIs).
With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives.
Learn more: us.gsk.com/en-us/media/press…
#News for #Investors and #Media: Today, we announced that the US FDA has granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome.
Learn more: gsk.to/4eoSdHf
GSK US retweeted
#News for #investors and #media:
We have entered an agreement to acquire clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio.
Find out more: gsk.to/4ooHOjy
#News for #investors and #media:
We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow.
Learn more: gsk.to/4dQBSLg.
Getting ahead of respiratory disease means relentless innovation, moving beyond just symptom management.
At #ATS2026, we're sharing 33 abstracts across our respiratory portfolio. Our focus: targeting underlying drivers of conditions like asthma, COPD, and refractory chronic cough to improve patient outcomes. Explore our science – a meaningful investment for patients, health systems, and societies.
GSK US retweeted
News for #Investors and #Media
Explore the key highlights from our Q1 2026 results announcement ⤵️
Find out more: gsk.to/4uelV7Y $GSK
GSK US retweeted
News for #Investors and #Media
Watch our CEO Luke Miels as he shares our strong Q1 performance and start to 2026.
Find out more: gsk.to/3OA31JU
$GSK #Q1Results